Akebia Therapeutics
AKBA
114 hedge funds and large institutions have $78.4M invested in Akebia Therapeutics in 2024 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 15 closing their positions.
93% more call options, than puts
Call options by funds: $910K | Put options by funds: $472K
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
37% more capital invested
Capital invested by funds: $57.4M → $78.4M (+$21M)
28% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 25
11% more funds holding
Funds holding: 103 → 114 (+11)
1.41% more ownership
Funds ownership: 26.85% → 28.26% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.75M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$1.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.06M |
| 4 |
State Street
Boston,
Massachusetts
|
+$912K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$540K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.14M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$562K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$287K |
| 4 |
Renaissance Technologies
New York
|
-$263K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$252K |
AKBA Hedge Fund Activity: Q3 2024 in Review
114 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2024, worth a combined $78.4M — up 37% from $57.4M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AKBA positions and 15 closed out — a net gain of 11 holders — while 32 added to existing stakes and 25 trimmed.
The largest buyer was BlackRock, adding an estimated $4.75M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $4.14M sold.
- 114 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2024, up from 103 in Q2 2024.
- Funds reported $78.4M of Akebia Therapeutics stock for Q3 2024, up 37% quarter-over-quarter.
- 26 funds opened new Akebia Therapeutics positions in Q3 2024 and 15 closed out, a net change of +11 holders.
- The largest Akebia Therapeutics buyer in Q3 2024 was BlackRock, an estimated $4.75M added.
- The largest Akebia Therapeutics seller in Q3 2024 was Acadian Asset Management, an estimated $4.14M sold.
Based on aggregated 13F filings for Q3 2024.